Genetic aberrations and survival in plasma cell leukemia

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Plasma cell leukemia (PCL) is a rare, aggressive hematological malignancy.
• PCL can arise as primary disease (pPCL) or secondary to multiple myeloma (sPCL).
• Understanding the distinct genetic profiles and survival outcomes of pPCL and sPCL is crucial for patient management.

Purpose of the Study:

• To investigate the genetic aberrations and survival patterns in patients with pPCL and sPCL.
• To compare the characteristics of pPCL and sPCL with multiple myeloma (MM).
• To identify prognostic factors influencing survival in plasma cell leukemia.

Main Methods:

• Analysis of genetic aberrations and clinical data from 80 patients with pPCL or sPCL.
• Comparison of findings with a cohort of 439 multiple myeloma cases.
• Statistical analysis to determine survival differences and identify predictive factors.

Main Results:

• pPCL occurs a decade earlier than sPCL (54.7 vs 65.3 years) and shows significantly longer overall survival (11.1 vs 1.3 months).
• Both pPCL and sPCL exhibit high prevalence of 14q32 (IgH) translocations; pPCL predominantly involves 11q13 (CCND1), while sPCL involves multiple oncogenes mirroring MM.
• TP53 inactivation is common in both (pPCL 56%, sPCL 83%), with frequent RAS mutations. MYC translocation predicts poor survival in pPCL.

Conclusions:

• Primary and secondary plasma cell leukemia are distinct entities with different natural histories, genetic landscapes, and prognoses.
• The specific genetic aberrations, particularly IgH translocation partners and TP53 status, differentiate pPCL and sPCL.
• These findings underscore the need for tailored therapeutic strategies based on the distinct biology of pPCL and sPCL.